A phase II study of nilotinib, a novel tyrosine kin ase inhibitor administered to patients with imatinib resistant or intolerant chronic myelogenous leukemia (CML) in chronic phase (CP), accelerated phase (AP) or blast crisis (BC) who have also failed dasatinib therapy.

被引：1
|
作者：
Giles, Francis
le Coutre, Philipp
Bhalla, Kapil
Rosti, Gianantonio
Ossenkopplele, G. J.
Alimena, Giuliana
Weitzman, Aaron
Rafferty, Teresa
Zheng, Ming
Kantarjian, Hagop
机构：
[1] MD Anderson Canc Ctr, Houston, TX USA
[2] Campus Virchow Klin, Berlin, Germany
[3] H Lee Moffitt Canc Ctr, Tampa, FL USA
[4] Univ Bologna Policlin, Azienda Osped, Bologna, Italy
[5] Vrije Univ Amsterdam, Med Ctr, Amsterdam, Netherlands
[6] Univ Roma La Sapienza, Azienda Policlin Umberto, Rome, Italy
[7] Novartis Pharmaceut, E Hanover, NJ USA
来源：
BLOOD | 2006年 / 108卷 / 11期
关键词：
D O I：
10.1182/blood.V108.11.2170.2170
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
2170
引用
收藏
页码：615A / 616A
页数：2
相关论文
共 50 条
  • [1] A phase II study of nilotinib administered to patients with imatinib resistant or intolerant chronic myelogenous leukemia (CML) in chronic phase (CP), accelerated phase (AP) or blast crisis (BC) who also failed dasatinib
    Giles, F. J.
    le Coutre, P.
    Bhalla, K.
    Rosti, G.
    Ossenkoppele, G.
    Alimena, G.
    Weitzman, A.
    Zheng, M.
    Kantarjian, H.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [2] A phase II study of nilotinib administered to imatinib resistant or intolerant patients with chronic myelogenous leukemia (CML) in accelerated phase (AP)
    le Coutre, P.
    Gattermann, N.
    Hochhaus, A.
    Larson, R.
    Weitzman, A.
    Haque, A.
    Giles, F.
    O'Brien, S. G.
    Kantarjian, H. M.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [3] A phase II study of nilotinib a novel tyrosine kinase inhibitor administered to imatinib-resistant or intolerant patients with chronic myelogenous leukemia (CML) in accelerated phase (AP).
    Kantarjian, Hagop M.
    Gattermann, Norbert
    Hochhaus, Andreas
    Larson, Richard
    Rafferty, Teresa
    Weitzman, Aaron
    Haque, Ariful
    Giles, Francis
    O'Brien, S. G.
    le Coutre, Philipp
    BLOOD, 2006, 108 (11) : 615A - 615A
  • [4] Nilotinib therapy after dasatinib failure in patients with imatinib-resistant or -intolerant chronic myeloid leukemia (CML) in chronic phase (CP), accelerated phase (AP) or blast crisis (BC)
    Giles, Francis J.
    le Coutre, Phillip
    Bhalla, Kapil N.
    Ossenkoppele, Gert
    Alimena, Giuliana
    Haque, Ariful
    Gallagher, Neil
    Kantarjian, Hagop M.
    BLOOD, 2007, 110 (11) : 311A - 312A
  • [5] A phase II study of nilotinib administered to imatinib resistant and intolerant patients with chronic myelogenous leukemia (CML) in chronic phase (CP)
    Rosti, G.
    le Coutre, P.
    Bhalla, K.
    Giles, F.
    Ossenkoppele, G.
    Hochhaus, A.
    Gattermann, N.
    Haque, A.
    Weitzman, A.
    Baccarani, M.
    Kantarjian, H.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [6] A phase II study of nilotinib, a novel tyrosine kinase inhibitor administered to imatinib-resistant and -intolerant patients with chronic myelogenous leukemia (CML) in chronic phase (CP).
    le Coutre, Philipp
    Bhalla, Kapil
    Giles, Francis
    Baccarani, Michele
    Ossenkoppele, Gert J.
    Hochhaus, Andreas
    Gattermann, Norbert
    Rafferty, Teresa
    Haque, Ariful
    Weitzman, Aaron
    Kantarjian, Hagop
    BLOOD, 2006, 108 (11) : 53A - 53A
  • [7] Pharmacokinetic analysis of nilotinib in Chinese chronic myelogenous leukemia (CML) patients (pts) with imatinib-resistant or-intolerant disease in blast crisis (BC), accelerated phase (AP) or chronic phase (CP)
    Zhou, L.
    Hu, P.
    Meng, F.
    Wang, J.
    Wang, C.
    Hu, Z.
    Shen, Z.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [8] A phase II study of nilotinib, a novel tyrosine vinase inhibitor administered to imatinib resistant or intolerant patients with chronic myelogenous leukemia (CML) in blast crisis (BC) or relapsed/refractory Ph plus acute lymphoblastic leukemia (ALL).
    Ottmann, Oliver
    Kantarjian, Hagop
    Larson, Richard
    le Courte, Philipp
    Baccarani, Michele
    Rafferty, Teresa
    Weitzman, Aaron
    Giles, Francis
    BLOOD, 2006, 108 (11) : 528A - 528A
  • [9] A phase II study of nilotinib,a novel tyrosine kinase inhibitor administered to imatinib-resistant and -intolerant patients with Philadelphia-positive chronic myelogenous leukemia in chronic phase
    Martinelli, G.
    Rosti, G.
    Le Coutre, P.
    Bhalla, K.
    Giles, F.
    Ossenkoppele, G.
    Hochhaus, A.
    Gatterman, N.
    Haque, A.
    Resta, D.
    Weitzman, A.
    Baccarani, M.
    Kantarjian, H.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 : 207 - 207
  • [10] Nilotinib in patients with imatinib-resistant or -intolerant chronic myelogenous leukemia in chronic phase (CML-CP): Updated phase II results
    Kantarjian, H. M.
    Giles, F. J.
    Hochhaus, A.
    Bhalla, K. N.
    Ossenkoppele, G. J.
    Gattermann, N.
    Haque, A.
    Gallagher, N.
    Castagnetti, F.
    le Coutre, P.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
12345